Rho-kinase as a novel gene therapeutic target in treatment of cold ischemia/reperfusion-induced acute lethal liver injury: effect on hepatocellular NADPH oxidase system.
In the transplant surgery, reactive oxygen species (ROS) from the reperfused tissue cause ischemia-reperfusion injury, resulting in the primary graft failure. We have recently reported that Rho-kinase, an effecter of the small GTPase Rho, plays an important role in the ROS production in the hyperacute phase of reperfusion; however, the sources and mechanisms of the ROS production remain to be elucidated. The aim of this study was to investigate the source of ROS production with a special reference to Rho-kinase to develop a new strategy against ischemia-reperfusion injury. In an in vivo rat model of liver transplantation, Kupffer cells in the graft were depleted using liposome-encapsulated dichloromethylene diphosphonate to examine the source of ROS production. The effect of adenoviral-mediated overexpression of a dominant-negative Rho-kinase (AdDNRhoK) in hepatocytes in the graft was also examined. Kupffer cells were not involved in the ROS production, whereas the AdDNRhoK transfection to hepatocytes significantly suppressed the ROS production. Furthermore, the ROS production was dose-dependently inhibited by apocynin, an NADPH oxidase inhibitor. Expression of DNRhoK also suppressed the release of pro-inflammatory cytokines, and ameliorated the lethal liver injury with a significant prolongation of the survival. These results suggest that the Rho-kinase-mediated pathway plays a crucial role in the ROS production through NADPH oxidase in hepatocytes during the hyperacute phase of reperfusion in vivo. Thus, Rho-kinase in hepatocytes may be a new therapeutic target for the prevention of primary graft failure in liver transplantation.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. satokos@surg2.med.kyushu-u.ac.jp
S
S
Shiotani
M
M
Shimada
A
A
Taketomi
Y
Y
Soejima
T
T
Yoshizumi
K
K
Hashimoto
H
H
Shimokawa
Y
Y
Maehara
D000098:Acetophenones / Q000627:therapeutic use; D000208:Acute Disease; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D003080:Cold Temperature; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D006085:Graft Survival; D022781:Hepatocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D007375:Interleukin-1 / Q000032:analysis / Q000276:immunology; D008102:Liver Circulation; D016031:Liver Transplantation; D008297:Male; D023421:Models, Animal; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051381:Rats; D011914:Rats, Inbred BN; D017382:Reactive Oxygen Species / Q000032:analysis / Q000378:metabolism; D015427:Reperfusion Injury / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D014161:Transduction, Genetic / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000276:immunology; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism
D000098:Acetophenones; D004791:Enzyme Inhibitors; D007375:Interleukin-1; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; C056165:acetovanillone; D019255:NADPH Oxidases; D054460:rho-Associated Kinases